Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 10/20 | 0.56 |
| ▸ | DRD3 | P35462 | 8/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 6/20 | 0.56 |
| ▸ | DRD1 | P21728 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8165643 | 0.92 | DRD2 (0.49) | SLC6A2SLC6A4DRD2DRD3ADRA1A | |
| SCHEMBL4250365 | 0.89 | DRD2 (0.45) | SLC6A2SLC6A4DRD2DRD3ADRA1A | |
| SCHEMBL8041607 | 0.88 | KDM4E (0.50) | DRD2DRD3ADRA1AHTR2AMEN1 | |
| SCHEMBL182966 | 0.88 | DRD2 (0.57) | DRD2DRD3DRD4DRD1HTR2A | |
| SCHEMBL1491165 | 0.87 | KDM4E (0.43) | SLC6A2SLC6A4DRD2DRD3ADRA1A | |
| SCHEMBL3407475 | 0.82 | SLC6A2 (0.61) | SLC6A2SLC6A4DRD2DRD3ADRA1A | |
| SCHEMBL182524 | 0.76 | PLA2G4B (0.54) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL11080260 | 0.76 | HTR1A (0.67) | DRD2DRD3DRD4HTR2AALDH1A1 | |
| SCHEMBL182622 | 0.75 | RAB9A (0.56) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3157625 | 0.75 | DRD2 (0.81) | DRD2DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975862-B2 | Arylpiperazine derivatives and methods of utilizing same | REVIVA PHARMACEUTICALS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170327477-A1 | ARYLPIPERAZINE DERIVATIVES AND METHODS OF UTILIZING SAME | REVIVA PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-9604944-B2 | Arylpiperazine derivatives and methods of utilizing same | REVIVA PHARMACEUTICALS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| EP-2400968-B1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | REVIVA PHARMACEUTICALS INC (US) | 2016-09-28 | — | — | EP | disclosed |
| US-20160229821-A1 | ARYLPIPERAZINE DERIVATIVES AND METHODS OF UTILIZING SAME | REVIVA PHARMACEUTICALS INC (US) | 2016-08-11 | — | — | US | disclosed |
| US-9255076-B2 | Arylpiperazine derivatives and methods of utilizing same | REVIVA PHARMACEUTICALS, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20150166493-A1 | ARYLPIPERAZINE DERIVATIVES AND METHODS OF UTILIZING SAME | REVIVA PHARMACEUTICALS INC (US) | 2015-06-18 | — | — | US | disclosed |
| US-8980883-B2 | Arylpiperazine derivatives and methods of utilizing same | REVIVA PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20150005298-A1 | ARYLPIPERAZINE DERIVATIVES AND METHODS OF UTILIZING SAME | REVIVA PHARMACEUTICALS INC (US) | 2015-01-01 | — | — | US | disclosed |
| US-8859552-B2 | Methods of utilizing arylpiperazine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20140155392-A1 | METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8461154-B2 | Methods of utilizing arylpiperazine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8431570-B2 | Methods of utilizing arylpiperazine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120220574-A1 | METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | BHAT LAXMINARAYAN (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220579-A1 | METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | BHAT LAXMINARAYAN (US) | 2012-08-30 | — | — | US | disclosed |
| US-8188076-B2 | Compositions, synthesis, and methods of utilizing arylpiperazine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| CN-102413830-A | Compositions, synthesis and methods utilizing arylpiperazine derivatives | REVIVA PHARMACEUTICALS INC | 2012-04-11 | — | — | CN | disclosed |
| EP-2400968-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | Reviva Pharmaceuticals, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010099502-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100216783-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327477-A1 | ARYLPIPERAZINE DERIVATIVES AND METHODS OF UTILIZING SAME | GRIK5, HTR5A, GRIK2 | SLC6A2 253/4885SLC6A4 279/4885DRD2 27/4885 |
| US-20160229821-A1 | ARYLPIPERAZINE DERIVATIVES AND METHODS OF UTILIZING SAME | GRIK5, HTR5A, GRIK2 | SLC6A2 253/4885SLC6A4 279/4885DRD2 27/4885 |
| US-20150005298-A1 | ARYLPIPERAZINE DERIVATIVES AND METHODS OF UTILIZING SAME | GRIK5, HTR5A, HTR2A | SLC6A2 170/4885SLC6A4 152/4885DRD2 10/4885 |
| US-20120220579-A1 | METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | HTR5A, GRIK5, HTR2A | SLC6A2 172/4885SLC6A4 124/4885DRD2 14/4885 |
| US-20120220574-A1 | METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | HTR5A, GRIK5, HTR2A | SLC6A2 172/4885SLC6A4 124/4885DRD2 14/4885 |
| US-20140155392-A1 | METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | HTR5A, GRIK5, HTR2A | SLC6A2 172/4885SLC6A4 124/4885DRD2 14/4885 |
| US-20150166493-A1 | ARYLPIPERAZINE DERIVATIVES AND METHODS OF UTILIZING SAME | GRIK5, HTR5A, HTR2A | SLC6A2 170/4885SLC6A4 152/4885DRD2 10/4885 |
| US-20100216783-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | GRIK5, HTR5A, KYNU | SLC6A2 589/4885SLC6A4 594/4885DRD2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.